{"schema_version":"1.0","type":"article","title":"再見癌症？癌症疫苗來了！莫德納單日暴漲176.97%","url":"https://drugnews.com.tw/articles/2026-08-21-moderna-merck-intismeran-phase3-melanoma.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-21-moderna-merck-intismeran-phase3-melanoma.md","lang":"zh-Hant","date":"2026-08-21","publish_at":"2026-08-21T08:00:00+08:00","updated_at":"2026-08-21","category":"商業分析系列","topic":"商業分析系列","tags":["Moderna","Merck","intismeran autogene","INTerpath-001","mRNA 癌症疫苗","黑色素瘤","個人化醫療","臨床三期"],"summary":"INTerpath-001 第三期頂線結果讓莫德納股價單日上漲 176.97%。真正被重新估價的，不只是一款黑色素瘤療法，而是個人化設計、製造、質控與臨床交付能否成為可擴張的平台。","key_points":[],"facts":[],"sections":["01｜176.97% 背後，三期到底證明了什麼？","02｜這不是貨架上的疫苗，而是一張患者專屬通緝令","03｜癌症疫苗跌倒多年，這次為何不一樣？","04｜為什麼偏偏是 mRNA？差異也要被工業管理","05｜市場一天買進的，其實是四筆價值","06｜個人化療法能不能賺錢，要看一張新報表","07｜暴漲 176.97%，也把風險一起拉高了","08｜台灣不是旁觀者，但概念股別先搶跑","結語｜癌症還沒說再見，市場先替「管理差異」開價","參考資料","免責聲明"],"references":[{"title":"[Nasdaq：MRNA 行情資料]","source":"","date":"","url":"https://api.nasdaq.com/api/quote/MRNA/info?assetclass=stocks"},{"title":"[Moderna：INTerpath-001 第三期預設期中頂線結果]","source":"","date":"","url":"https://news.modernatx.com/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-plus-keytruda-met-endpoints-of-rfs-and-dmfs-in-melanoma"},{"title":"[Merck：INTerpath-001 第三期 RFS 與 DMFS 結果公告]","source":"","date":"","url":"https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/"},{"title":"[ClinicalTrials.gov：INTerpath-001，NCT05933577]","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT05933577"},{"title":"[Merck／Moderna：KEYNOTE-942 第二期五年追蹤]","source":"","date":"","url":"https://www.merck.com/news/moderna-and-merck-present-5-year-data-for-intismeran-autogene-in-combination-with-keytruda-pembrolizumab-in-patients-with-high-risk-stage-iii-iv-melanoma-following-complete-resection-at-the-20/"},{"title":"[Moderna 2025 Form 10-K]","source":"","date":"","url":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/mrna-20251231.htm"},{"title":"[Merck 2025 Form 10-K]","source":"","date":"","url":"https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm"},{"title":"查證截止日：2026 年 8 月 20 日。","source":"","date":"","url":""}],"images":[{"alt":"圖 1｜INTerpath-001 第三期同時達到 RFS 與 DMFS 終點，但風險比、存活曲線與總生存期仍未完整揭露","url":"https://drugnews.com.tw/assets/articles/moderna-merck-intismeran-phase3-melanoma/figure-02.png"},{"alt":"圖 2｜每位患者都要經過腫瘤與血液取樣、定序、新抗原挑選、mRNA 製造、質控及回院給藥","url":"https://drugnews.com.tw/assets/articles/moderna-merck-intismeran-phase3-melanoma/figure-01.png"},{"alt":"圖 3｜個人化 mRNA 藥物商業化需要新抗原預測、製造、個別批次質控與冷鏈臨床交付四套系統","url":"https://drugnews.com.tw/assets/articles/moderna-merck-intismeran-phase3-melanoma/figure-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/moderna-merck-intismeran-phase3-melanoma/cover-1400.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-21）。再見癌症？癌症疫苗來了！莫德納單日暴漲176.97%。https://drugnews.com.tw/articles/2026-08-21-moderna-merck-intismeran-phase3-melanoma.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-08-21-moderna-merck-intismeran-phase3-melanoma-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}